**Lower Thiol, Glutathione, and Glutathione Peroxidase Levels in Prostate Cancer: A Meta-Analysis Study**

Nattanan Sajjaboontawee1, Thitiporn Supasitthumrong2, Chavit Tunvirachaisakul3, Kanyapak Nantachai4, Edna Maria Vissoci Reiche5, Andréa Name Colado Simão6, Michael Maes7

1. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
2. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
3. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
4. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
5. Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, Londrina State University, Londrina, Paraná, Brazil.
6. Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, Londrina State University, Londrina, Paraná, Brazil.
7. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

**ESF1 Table 1. Specific search for each database**

|  |
| --- |
| **PubMed/Medline** |
| ((prostate cancer\* OR PCa\* OR benign prostatic hyperplasia OR BPH) **AND** (thiol OR glutathione OR glutathione peroxidase OR glutathione reductase OR glutathione-s-transferase)) **45** |
| ***SCOPUS*** |
| TITLE-ABS-KEY (prostate cancer\* OR benign prostatic hyperplasia) AND TITLE-ABS-KEY (thiol OR glutathione OR glutathione peroxidase OR glutathione reductase OR glutathione-s-transferase) AND ( LIMIT-TO ( PUBYEAR , 2020 ) OR( LIMIT-TO ( PUBYEAR , 2019 ) OR( LIMIT-TO ( PUBYEAR , 2018 ) OR ( LIMIT-TO ( PUBYEAR , 2017 ) OR LIMIT-TO ( PUBYEAR , 2016 ) OR LIMIT-TO ( PUBYEAR , 2015 ) OR LIMIT-TO ( PUBYEAR , 2014 ) OR LIMIT-TO ( PUBYEAR , 2013 ) OR LIMIT-TO ( PUBYEAR , 2012 ) OR LIMIT-TO ( PUBYEAR , 2011 ) OR LIMIT-TO ( PUBYEAR , 2010 ) OR LIMIT-TO ( PUBYEAR , 2009 ) OR LIMIT-TO ( PUBYEAR , 2008 ) OR LIMIT-TO ( PUBYEAR , 2007 ) OR LIMIT-TO ( PUBYEAR , 2006 ) OR LIMIT-TO ( PUBYEAR , 2005 ) OR LIMIT-TO ( PUBYEAR , 2004 ) OR LIMIT-TO ( PUBYEAR , 2003 ) OR LIMIT-TO ( PUBYEAR , 2002 ) OR LIMIT-TO ( PUBYEAR , 2001 ) OR LIMIT-TO ( PUBYEAR , 2000 ) OR LIMIT-TO ( PUBYEAR , 1999 ) OR LIMIT-TO ( PUBYEAR , 1998 ) OR LIMIT-TO ( PUBYEAR , 1997 ) OR LIMIT-TO ( PUBYEAR , 1996 ) OR LIMIT-TO ( PUBYEAR , 1995 ) OR LIMIT-TO ( PUBYEAR , 1994 ) OR LIMIT-TO ( PUBYEAR , 1993 ) OR LIMIT-TO ( PUBYEAR , 1992 ) OR LIMIT-TO ( PUBYEAR , 1991 ) OR LIMIT-TO ( PUBYEAR , 1990 ) ) AND ( LIMIT-TO ( DOCTYPE , "ar" ) ) AND ( LIMIT-TO ( LANGUAGE , "English" ) ) **68** |
| **Google Scholar** |
| Any Field: **prostate cancer OR benign prostatic hyperplasia** **AND** (Any Field: \***Thiol**\* OR Any Field: \***Glutathione**\* OR Any Field: Glutathione peroxidase OR Any Field: \*glutathione reductase\* OR Any Field: glutathione-s-transferase) **AND** Population Group: Human **112** |
| **Cochrane Database of Systematic Reviews** |
| TITLE-ABS-KEY (prostate cancer\* or benign prostatic hyperplasia)  **AND** (thiol OR glutathione OR glutathione peroxidase OR glutathione reductase OR glutathione-s-transferase) AND ( LIMIT-TO ( PUBYEAR , 2020 ) OR( LIMIT-TO ( PUBYEAR , 2019 ) OR( LIMIT-TO ( PUBYEAR , 2018 ) OR ( LIMIT-TO ( PUBYEAR , 2017 ) OR LIMIT-TO ( PUBYEAR , 2016 ) OR LIMIT-TO ( PUBYEAR , 2015 ) OR LIMIT-TO ( PUBYEAR , 2014 ) OR LIMIT-TO ( PUBYEAR , 2013 ) OR LIMIT-TO ( PUBYEAR , 2012 ) OR LIMIT-TO ( PUBYEAR , 2011 ) OR LIMIT-TO ( PUBYEAR , 2010 ) OR LIMIT-TO ( PUBYEAR , 2009 ) OR LIMIT-TO ( PUBYEAR , 2008 ) OR LIMIT-TO ( PUBYEAR , 2007 ) OR LIMIT-TO ( PUBYEAR , 2006 ) OR LIMIT-TO ( PUBYEAR , 2005 ) OR LIMIT-TO ( PUBYEAR , 2004 ) OR LIMIT-TO ( PUBYEAR , 2003 ) OR LIMIT-TO ( PUBYEAR , 2002 ) OR LIMIT-TO ( PUBYEAR , 2001 ) OR LIMIT-TO ( PUBYEAR , 2000 ) OR LIMIT-TO ( PUBYEAR , 1999 ) OR LIMIT-TO ( PUBYEAR , 1998 ) OR LIMIT-TO ( PUBYEAR , 1997 ) OR LIMIT-TO ( PUBYEAR , 1996 ) OR LIMIT-TO ( PUBYEAR , 1995 ) OR LIMIT-TO ( PUBYEAR , 1994 ) OR LIMIT-TO ( PUBYEAR , 1993 ) OR LIMIT-TO ( PUBYEAR , 1992 ) OR LIMIT-TO ( PUBYEAR , 1991 ) OR LIMIT-TO ( PUBYEAR , 1990 ) ) **27** |

**ESF Table 2. Total excluded papers and reasons**

|  |  |  |
| --- | --- | --- |
|  | **1rst author (year)** | **Reason to be excluded** |
| 1 | Battisti (2011) | Data were shown in graphs, and numerical data were not provided upon request. |
| 2 | Cramer (2017) | Did not match the study interest. |
| 3 | Freitas (2011) | The study was an *in-vitro* study. |
| 4 | Heckbert (1992) | Patients with prostate cancer were included with other types of cancer. No individual data were provided. |
| 5 | Hietanen (1994) | Full-text was not provided upon request. |
| 6 | Laur (2008) | Did not have data on included antioxidant levels. |
| 7 | Rao (1999) | Data were shown in graphs, and numerical data were not provided upon request. |
| 8 | Richie (2014) | Did not have numerical data of GSH levels. |
| 9 | Topaktas (2019) | Did not have a healthy control group. |
| 10 | Topaktas (2019) | Did not have a healthy control group. |

1. Battisti V, Maders L, Bagatini M, Reetz L, Chiesa J, Battisti I, et al. Oxidative stress and antioxidant status in prostate cancer patients: Relation to Gleason score, treatment and bone metastasis. Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie. 2011;65:516-24.
2. Cramer SL, Saha A, Liu J, Tadi S, Tiziani S, Yan W, et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nature medicine. 2017;23(1):120-7.
3. Freitas M, Baldeiras I, Proença T, Alves V, Mota-Pinto A, Sarmento-Ribeiro A. Oxidative stress adaptation in aggressive prostate cancer may be counteracted by the reduction of glutathione reductase. FEBS open bio. 2012;2:119-28.
4. Heckbert SR, Weiss NS, Hornung SK, Eaton DL, Motulsky AG. Glutathione S-Transferase and Epoxide Hydrolase Activity in Human Leukocytes in Relation to Risk of Lung Cancer and Other Smoking-Related Cancers. JNCI: Journal of the National Cancer Institute. 1992;84(6):414-22.
5. Hietanen E, Bartsch H, Béréziat JC, Camus AM, McClinton S, Eremin O, et al. Diet and oxidative stress in breast, colon and prostate cancer patients: a case-control study. Eur J Clin Nutr. 1994;48(8):575-86.
6. Laur J, Abud M, Fontana C, Silva J, Cisella Y, Elizalde R, et al. Poder antioxidante y daño celular en el carcinoma de próstata. Archivos Españoles de Urología (Ed impresa). 2008;61.
7. Rao AV, Fleshner N, Agarwal S. Serum and Tissue Lycopene and Biomarkers of Oxidation in Prostate Cancer Patients: A Case-Control Study. Nutrition and Cancer. 1999;33(2):159-64.
8. Richie J, Das A, Calcagnotto A, Sinha R, Neidig W, Liao J, et al. Comparative Effects of Two Different Forms of Selenium on Oxidative Stress Biomarkers in Healthy Men: A Randomized Clinical Trial. Cancer prevention research (Philadelphia, Pa). 2014;7.
9. Topaktaş R, Ürkmez A, Kutluhan MA, Çalışkan S, Erel Ö. Does plasma thiol and disulphide be a new marker for prostate cancer in prostate-specific antigen level between 10 and 20 ng/ml? The Aging Male. 2019:1-5.
10. Topaktaş R, Urkmez A, Kutluhan M, Akkoc A, ÖZsoy E, Erel O. Prostat Kanseri Tanısında Thiol/Disülfid Dengesi PSA'ya Ek Bir Serum Belirteç Olarak Güvenilir midir? Acta Medica Alanya. 2019.

**ESF Table 3. Systematic Review**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Authors, year** | **Antioxidant levels** | **n (PCa, BPH, HC)** |  | | **Age (years)** | | **Diagnotic Criteria** | | **Country** | **Latitude** | **Ethnicity** | **Type of Sample** | **Results** |
| **PCa** | **BPH** | | **HC** | **PCa** | **BPH** |  |  |  |  |  |
| **Abou Ghalia and Fouad**  **(2000)** | GSH (mM/L), GPx (U/g), GST, GR (U/L) | 41 (21, 10, 10) | NR | NR | | NR | Biopsy | Biopsy | Egypt | 30.076 | NR | Blood | PCa=BPH=HC: GSH, GR. PCa>HC, BPH=HC: GPx, PCa<BPH=HC: GST. |
| **Ahmad et al (2012)** | GST, GR (U/mg), GSH (umol/mg) | 90 (N/A, 45, 45) | N/A | 57-83 | | 57-83 | N/A | Urinary symptoms, DRE, PSA, TRUS, biopsy | India | 27.9186 | Asian | Plasma | BPH<HC: GST, GR, GSH |
| **Ahmed Amar et al**  **(2018)** | GSH (mmol/gpr) | 50 (25, N/A, 25) | 45-70 | N/A | | 45-70 | NR | N/A | Turkey | 38.5012 | Asian | Serum | PCa<HC: GSH |
| **Akinloye et al (2009)** | GSH (ug/ml) | 92 (42, N/A, 50) | 24-73 | N/A | | 24-73 | PSA | N/A | Turkey | 7.3569 | Black | Blood | PCa<HC: GSH |
| **Arsova-Sarafinovska et al**  **(2009)** | GPx (U/ml) | 149 (34, 100, 15), 163 (73, 67, 23) | 67.5, 68.9 | 65.4, 71 | | 60.3, 69.6 | Biopsy | Biopsy | Turkey, Macedonia | 39.9783, 42.005 | Asian, Caucasian | Erythrocytes | PCa<BPH<HC: GPx |
| **Asare et al (2018)** | GPx (ng/ml) | 90 (N/A, 60, 30) | N/A | 65.8 | | 51.9 | N/A | Biopsy | Ghana | 5.5684 | Black | Serum | BPH<HC: GPx |
| **Aydin et al (2006)** | GPx (U/ml) | 85 (25, 36, 24) | 67.5 | 64.3 | | 65 | DRE, PSA, transrectal ultrasound, biopsy | Biopsy | Turkey | 39.9783 | Asian | Erythrocytes | PCa<BPH=HC:GPx |
| **Duru et al (2014)** | GPx (U/L) | 104 (40, 32, 32) | 53-85 | 53-85 | | 53-85 | NR | NR | Nigeria | 6.4584 | Black | Plasma | PCa=BPH<HC: GPx |
| **Hacer et al (2004)** | GSH (umol/g), GPx, GR, GST (U/g) | 41 (21, N/A, 20) | 69.4 | N/A | | 63.7 | NR | N/A | Turkey | 41.004 | Asian | Erythrocytes | PCa<HC: GSH, GPx, GR. PCa>HC: GST. |
| **Hanikoglu et al**  **(2016)** | SH (umol/L) | 35 (18, N/A, 17) | 65.5 | N/A | | 66.7 | NR | N/A | Turkey | 36.8945 | Asian | Serum | PCa<HC: SH |
| **Hardell et al (1995)** | GPx (ukat/g) | 316 (164, 152, N/A) | 70 | 69 | | N/A | NR | NR | Sweden | 60.1282 | Caucasian | Erythrocytes | PCa=BPH: GPx |
| **Koike et al (2020)** | SH (uM) | 204 (73, 67, 64) | 61.8 | 63.3 | | 51.7 | Biopsy | Biopsy | Brazil | -23.3045 | NR | Serum | PCa<BPH<HC: SH |
| **Kotrikadze et al**  **(2008)** | GPx, GR (uM/g/min), GSH (uM/L) | 45 (15, 15, 15) | 60-75 | 60-75 | | 60-75 | DRE, biopsy, echographic examination | DRE, biopsy, echographic examination | Georgia | 41.7151 | Caucasian | Erythrocytes | PCa<HC, BPH>HC: GPx. PCa>HC, BPH>HC: GR, GSH. |
| **Solakhan et al (2019)** | SH (umol/L) | 80 (25, 30, 25) | 70.6 | 60.5 | | 64.3 | Gleason score, PSA | PSA | Turkey | 37.0751 | Asian | Serum | PCa=BPH<HC: SH |
| **Sonmez et al (2018)** | SH (umol/L) | 89 (29, 30, 30) | 69.5 | 69.7 | | 66.6 | PSA, DRE, TRUS, Gleason score | PSA, DRE, TRUS | Turkey | 37.8573 | Asian | Serum | BPH<PCa<HC: SH |
| **Srivastava and Mittal**  **(2005)** | GSH (mg %), GPx (U/L), GST (U/ml.min) | 125 (45, 55, 25) | 61.9 | 59.6 | | 60.5 | Clinical, biomedical, and histological criteria | Clinical, biomedical, and histological criteria | India | 28.6925 | Asian | Serum | PCa<BPH<HC: GSH, GPx. BPH>PCa>HC: GST. |
| **Surapaneni and Ramana**  **(2006)** | GSH (mg/g), GST (umol/dl) | 60 (30, N/A, 30) | NR | N/A | | NR | Histological criteria | N/A | India | 15.9129 | Asian | Erythrocytes, Plasma | PCa<HC: GSH, PCa=HC: GST |
| **Wozniak et al (2012)** | GPx (U/g) | 90 (60, N/A, 30) | 67.4 | N/A | | 61.9 | NR | N/A | Poland | 53.0195 | Caucasian | Erythrocytes | PCa<HC: GPx |
| **Yilmaz et al (2003)** | GPx (U/ml) | 121 (21, 50, 50) | 66 (Median) | 63.5 (Median) | | 66 (Median) | DRE, PSA, Transrectal ultrasonography, biopsy Gleason sum | NR | Turkey | 39.9783 | Asian | Erythrocytes | PCa=BPH<HC: GPx |
| **Zachara et al (2004)** | GPx (U/L) | 113 (39, 42, 32) | 61 | 68 | | 48 | NR | NR | Poland | 52.7993 | Caucasian | Erythrocytes, plasma | BPH<PCa=HC: GPx (erythrocytes). PCa<BPH=HC: GPx (plasma) |

1. Abou Ghalia AH, Fouad IM. Glutathione and its metabolizing enzymes in patients with different benign and malignant diseases. Clinical biochemistry. 2000;33(8):657-62.
2. Ahmad M, Suhail N, Mansoor T, Banu N, Ahmad S. Evaluation of oxidative stress and DNA damage in benign prostatic hyperplasia patients and comparison with controls. Indian J Clin Biochem. 2012;27(4):385-8.
3. Ahmed Amar SA, Eryilmaz R, Demir H, Aykan S, Demir C. Determination of oxidative stress levels and some antioxidant enzyme activities in prostate cancer. The Aging Male. 2019;22(3):198-206.
4. Akinloye O, Adaramoye O, Kareem O. Changes in antioxidant status and lipid peroxidation in Nigerian patients with prostate carcinoma. Pol Arch Med Wewn. 2009;119(9):526-32.
5. Arsova-Sarafinovska Z, Eken A, Matevska-Geshkovska N, Erdem O, Sayal A, Savaşer A, et al. Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clinical biochemistry. 2009;42:1228-35.
6. Asare GA, Andam SE, Asare-Anane H, Ammanquah S, Anang-Quartey Y, Afriyie DK, et al. Lipid associated antioxidants: arylesterase and paraoxonase-1 in benign prostatic hyperplasia treatment-naïve patients. Prostate Int. 2018;6(1):36-40.
7. Aydin A, Arsova-Sarafinovska Z, Sayal A, Eken A, Erdem O, Erten K, et al. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clinical biochemistry. 2006;39:176-9.
8. Duru R, Njoku O, Maduka I. Oxidative Stress Indicators in Patients with Prostate Disorders in Enugu, South-East Nigeria. BioMed Research International. 2014;2014:313015.
9. Hacer İA, Zeynep AA, Can Ö, Riza KA, Dildar K, Tülay A. The effect of prostate cancer and antianrogenic therapy on lipid peroxidation and antioxidant systems. International Urology and Nephrology. 2003;36(1):57-62.
10. Hanikoglu F, Hanikoglu A, Kucuksayan E, Alisik M, Gocener A, Erel O, et al. Dynamic Thiol/Disulphide Homeostasis Before and After Radical Prostatectomy in Patients with Prostate Cancer. Free radical research. 2016;50:1-10.
11. Hardell L, Degerman A, Tomic R, Marklund SL, Bergfors M. Levels of selenium in plasma and glutathione peroxidase in erythrocytes in patients with prostate cancer or benign hyperplasia. European Journal of Cancer Prevention. 1995;4(1).
12. Kotrikadze N, Alibegashvili M, Zibzibadze M, Abashidze N, Chigogidze T, Managadze L, et al. Activity and content of antioxidant enzymes in prostate tumors. Experimental oncology. 2008;30:244-7.
13. Solakhan M, Çiçek H, Orhan N, Yıldırım M. Role of native Thiol, total Thiol and dynamic Disulphide in diagnosis of patient with prostate cancer and prostatitis. International braz j urol. 2019;45.
14. Sönmez MG, Kozanhan B, Deniz ÇdD, Gögˇer YE, Kilinç MT, Neşeliogˇlu S, et al. Is oxidative stress measured by thiol/disulphide homeostasis status associated with prostate adenocarcinoma? Cent Eur J Immunol. 2018;43(2):174-9.
15. Srivastava D, Mittal RD. Free radical injury and antioxidant status in patients with benign prostate hyperplasia and prostate cancer. Indian J Clin Biochem. 2005;20:162-5.
16. Surapaneni KM, Venkata GR. Lipid peroxidation and antioxidant status in patients with carcinoma of prostate. Indian J Physiol Pharmacol. 2006;50(4):350-4.
17. Woźniak A, Masiak R, Szpinda M, Mila-Kierzenkowska C, Woźniak B, Makarewicz R, et al. Oxidative stress markers in prostate cancer patients after HDR brachytherapy combined with external beam radiation. Oxid Med Cell Longev. 2012;2012:789870-.
18. Yilmaz MI, Saglam K, Sonmez A, Gok DE, Basal S, Kilic S, et al. Antioxidant system activation in prostate cancer. Biological Trace Element Research. 2004;98(1):13-9.
19. Zachara BA, Szewczyk-Golec K, Tyloch J, Wolski Z, Szylberg T, Stepien S, et al. Blood and tissue selenium concentrations and glutathione peroxidase activities in patients with prostate cancer and benign prostate hyperplasia. Neoplasma. 2005;52(3):248-54.
20. Koike A, Robles BEF, Bonacim AG da S, Alcantara CC de, Reiche EMV, Dichi I, Maes M, Cecchini R, Simão ANC. Thiol groups as a biomarker for the diagnosis and prognosis of prostate cancer. Scientific Reports. 2020, in press.